Evidence for MedTech - the Swedish case of health technology assessment and a new tool to navigate ithealth technology assessmentIF2.82025-01-090OA
Exploring the discrepancies between clinical trials and real-world data: A small-cell lung cancer studyCTS-CLINICAL AND TRANSLATIONAL SCIENCEIF2.82024-08-071OA
Population Pharmacokinetic Analysis and Simulation of Alternative Dosing Regimens for Biosimilars to Adalimumab and Etanercept in Patients with Rheumatoid ArthritisPHARMACEUTICSIF5.52024-05-230OAAI
Diagnosing an overcrowded emergency department from its Electronic Health RecordsSCIENTIFIC REPORTSIF3.92024-04-302OAAI
A novel analytical framework for risk stratification of real-world data using machine learning: A small cell lung cancer studyCTS-CLINICAL AND TRANSLATIONAL SCIENCEIF2.82022-07-297OAAI
Developing Clinically Relevant Dissolution Specifications (CRDSs) for Oral Drug Products: Virtual Webinar SeriesPHARMACEUTICSIF5.52022-05-0710OAAI
Review article: time to revisit Child-Pugh score as the basis for predicting drug clearance in hepatic impairmentALIMENTARY PHARMACOLOGY & THERAPEUTICSIF6.72021-07-0438OAAI
Model-Informed Precision Dosing: Background, Requirements, Validation, Implementation, and Forward Trajectory of Individualizing Drug TherapyANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, VOL 61, 2021IF02021-01-06101OAAI
Application of the Nested Enzyme-Within-Enterocyte (NEWE) Turnover Model for Predicting the Time Course of Pharmacodynamic EffectsCPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGYIF32020-09-281OAAI
Global Sensitivity Analysis of the Rodgers and Rowland Model for Prediction of Tissue: Plasma Partitioning Coefficients: Assessment of the Key Physiological and Physicochemical Factors That Determine Small-Molecule Tissue DistributionAAPS JOURNALIF3.72020-02-0321OAAI
The nested enzyme-within-enterocyte (NEWE) turnover model for predicting dynamic drug and disease effects on the gut wallEUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCESIF4.72019-04-014OAAI
The Impact of Formulation, Delivery, and Dosing Regimen on the Risk of Drug-Drug InteractionsCLINICAL PHARMACOLOGY & THERAPEUTICSIF5.52019-03-215OAAI
Towards Further Verification of Physiologically-Based Kidney Models: Predictability of the Effects of Urine-Flow and Urine-pH on Renal ClearanceJOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICSIF3.82019-02-0119OAAI
What Does it Take to Make Model-Informed Precision Dosing Common Practice? Report from the 1st Asian Symposium on Precision DosingAAPS JOURNALIF3.72019-01-0928OAAI
Ratifying the dosage and duration of levo-bupivacaine infusion by the caudal-epidural route in infants aged three to six monthsBRITISH JOURNAL OF ANAESTHESIAIF9.22018-05-010OAAI
Implications of intercorrelation between hepatic CYP3A4-CYP2C8 enzymes for the evaluation of drug-drug interactions: a case study with repaglinideBRITISH JOURNAL OF CLINICAL PHARMACOLOGYIF32018-03-0616OAAI
Virtual bioequivalence for achlorhydric subjects: The use of PBPK modelling to assess the formulation-dependent effect of achlorhydriaEUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCESIF4.72017-11-0145OAAI
Why has model-informed precision dosing not yet become common clinical reality? lessons from the past and a roadmap for the futureCLINICAL PHARMACOLOGY & THERAPEUTICSIF5.52017-04-04181OAAI
IMI - oral biopharmaceutics tools project - evaluation of bottom-up PBPK prediction success part 1: Characterisation of the OrBiTo database of compoundsEUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCESIF4.72017-01-0134OAAI